{
    "symbol": "MGNX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-05 18:08:21",
    "content": " As described in our release this afternoon, MacroGenics total revenue consisting primarily of revenue from collaborative agreements was $41.7 million for the quarter ended September 30, 2022, compared to total revenue of $15.7 million for the quarter ended September 30, 2021. Revenue for the quarter ended September 30, 2022, included $30 million in milestone payments from Incyte related to retifanlimab, which they licensed from us in 2017. Revenue for the quarter ended September 30, 2022, also included MARGENZA net sales of $4.4 million compared to $3.6 million for the quarter ended September 30, 2021. Our research and development expenses were $48.2 million for the quarter ended September 30, 2022, compared to $49.8 million for the quarter ended September 30, 2021. Our selling, general and administrative expenses were $15.4 million for the quarter ended September 30, 2022, compared to $17.2 million for the quarter ended September 30, 2021. Finally, in terms of our cash runway, we anticipate that our cash, cash equivalents and marketable securities balance as of September 30, 2022, the $60 million subsequently received from Gilead, projected and anticipated payments from partners, product revenues as well as anticipated savings from our previously announced corporate restructuring plan, should extend our cash runway into mid-2024."
}